不同有创通气启动阈值的随机试验潜在价值何在?一项卫生经济学分析
该研究基于模型进行成本-效用估算与个体水平模拟的价值信息分析,对象为入住重症监护室并接受无创氧疗的成人低氧性呼吸衰竭患者,支付方为公共医疗体系。主要情景比较假设阈值A(增加有创通气使用并改善生存)与常规治疗,阈值B(减少有创通气使用且生存相似)与常规治疗。阈值A因医院生存率改善(78.1% vs 75.1%)虽增加有创通气使用(62% vs 30%)和终身成本(86,900 vs 75,500加元)仍具成本效果;阈值B因生存相似(74.5% vs 74.6%)但减少有创通气使用(20.2% vs 27.6%)和终身成本(71,700 vs 74,700加元)也具成本效果。价值信息分析显示,10年内400人随机试验的预期社会价值在两种情景下均≥13.5亿加元。
要点
- 主要情景:阈值A较常规治疗提高医院生存率(78.1% vs 75.1%),尽管有创通气使用更多(62% vs 30%)、终身成本更高(86,900 vs 75,500加元),仍具成本效果。
- 次要情景:阈值B较常规治疗生存率相似(74.5% vs 74.6%),但有创通气使用更少(20.2% vs 27.6%)、终身成本更低(71,700 vs 74,700加元),具成本效果。
- 价值信息分析:10年内比较有创通气阈值与常规治疗的400人随机试验,在两种情景下对加拿大社会的预期价值均≥13.5亿加元。
- 支付意愿假设为每质量调整生命年100,000加元;场景为资源不受限的非大流行时期重症监护室。
适用人群与场景
- 入住重症监护室并接受无创氧疗的成人低氧性呼吸衰竭患者
- 场景为能够提供有创通气且在非大流行常规实践中资源不受限的重症监护室
研究设计与关键结果
- 研究设计:基于模型的成本-效用估算,采用个体水平模拟与价值信息分析,支付方为公共医疗体系
- 主要情景:假设阈值A较常规治疗增加有创通气使用并改善生存;阈值A医院生存率78.1% vs 常规治疗75.1%,有创通气使用62% vs 30%,终身成本86,900 vs 75,500加元,阈值A具成本效果
- 次要情景:假设阈值B较常规治疗减少有创通气使用且生存相似;阈值B生存率74.5% vs 常规治疗74.6%,有创通气使用20.2% vs 27.6%,终身成本71,700 vs 74,700加元,阈值B具成本效果
- 支付意愿假设为每质量调整生命年100,000加元
- 价值信息分析:10年内比较有创通气阈值与常规治疗的400人随机试验,在两种情景下对加拿大社会的预期价值均≥13.5亿加元
证据类型、等级与局限
- 证据类型:基于模型的成本-效用估算与价值信息分析
- 局限:原文未报告局限性
对床旁实践的改变
- 作者认为,识别与常规治疗相比要么提高生存率、要么减少有创通气且不降低生存率的阈值,对社会具有极高价值。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: To estimate the expected value of undertaking a future randomized controlled trial of thresholds used to initiate invasive ventilation compared with usual care in hypoxemic respiratory failure.
PERSPECTIVE: Publicly funded healthcare payer.
SETTING: Critical care units capable of providing invasive ventilation and unconstrained by resource limitations during usual (nonpandemic) practice.
METHODS: We performed a model-based cost-utility estimation with individual-level simulation and value-of-information analysis focused on adults, admitted to critical care, receiving noninvasive oxygen. In the primary scenario, we compared hypothetical threshold A to usual care, where threshold A resulted in increased use of invasive ventilation and improved survival compared with usual care. In the secondary scenario, we compared hypothetical threshold B to usual care, where threshold B resulted in decreased use of invasive ventilation and similar survival compared with usual care. We assumed a willingness-to-pay of 100,000 Canadian dollars (CADs) per quality-adjusted life year.
RESULTS: In the primary scenario, threshold A was cost-effective compared with usual care due to improved hospital survival (78.1% vs. 75.1%), despite more use of invasive ventilation (62% vs. 30%) and higher lifetime costs (86,900 vs. 75,500 CAD). In the secondary scenario, threshold B was cost-effective compared with usual care due to similar survival (74.5% vs. 74.6%) with less use of invasive ventilation (20.2% vs. 27.6%) and lower lifetime costs (71,700 vs. 74,700 CAD). Value-of-information analysis showed that the expected value to Canadian society over 10 years of a 400-person randomized trial comparing a threshold for invasive ventilation to usual care in hypoxemic respiratory failure was 1.35 billion CAD or more in both scenarios.
CONCLUSIONS: It would be highly valuable to society to identify thresholds that, in comparison to usual care, either increase survival or reduce invasive ventilation without reducing survival.
参考来源
- Yarnell CJ, Barrett K, Heath A, et al. What Is the Potential Value of a Randomized Trial of Different Thresholds to Initiate Invasive Ventilation? A Health Economic Analysis. Crit Care Explor. 2024. PMID: 38836575. doi:10.1097/CCE.0000000000001098
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。